Metabolomic Alterations Associated with Adjunctive Hydrogen Gas Inhalation During Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancer: A Pilot Study.
Imjai Chitapanarux, Narongchai Autsavapromporn, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Apidet Duangya, Tanin Lertsiriladakul, Atikorn Panya, Atchara Paemanee · Cancers · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 20 patients with adjunctive H₂ gas inhalation (Group B), patients receiving adjunctive H₂ gas inhalation tended to exhibit numerically lower frequencies of moderate treatment-related toxicities, fewer chemotherapy delays, and a shorter overall treatment duration than those receiving CCRT alone. Consistent with these findings, direct between-group comparison of within-subject changes (Δ = post – pre) indicated a numerically smaller reduction in serum uric acid levels in the adjunctive H₂ gas inhalation group; however, this difference did not reach statistical significance. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 20 patients with adjunctive H₂ gas inhalation (Group B). Patients receiving adjunctive H₂ gas inhalation tended to exhibit numerically lower frequencies of moderate treatment-related toxicities, fewer chemotherapy delays, and a shorter overall treatment duration than those receiving CCRT alone. Consistent with these findings, direct between-group comparison of within-subject changes (Δ = post – pre) indicated a numerically smaller reduction in serum uric acid levels in the adjunctive H₂ gas inhalation group; however, this difference did not reach statistical significance.
What the Researchers Studied
The researchers studied 20 patients with adjunctive H₂ gas inhalation (Group B). The study used a randomized human clinical trial.
What Effects Did Molecular Hydrogen Have?
Twenty patients were prospectively randomized to receive either standard CCRT alone (Group A) or CCRT combined with adjunctive H₂ gas inhalation (Group B). Patients receiving adjunctive H₂ gas inhalation tended to exhibit numerically lower frequencies of moderate treatment-related toxicities, fewer chemotherapy delays, and a shorter overall treatment duration than those receiving CCRT alone. Consistent with these findings, direct between-group comparison of within-subject changes (Δ = post – pre) indicated a numerically smaller reduction in serum uric acid levels in the adjunctive H₂ gas inhalation group; however, this difference did not reach statistical significance. The authors concluded that adjunctive H₂ gas inhalation during CCRT may be associated with reduced moderate treatment-related toxicities and exploratory changes in systemic metabolic profiles in patients with LAHNC.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 20 patients with adjunctive H₂ gas inhalation (Group B). The reported sample size was 20. The study used a randomized human clinical trial.
Limitations and Safety
Reported limitations: The relatively small sample size limits statistical power and generalizability, and validation in larger, independent cohorts is required. Another limitation is the heterogeneity in tumor site, stage, chemotherapy regimen, and patient characteristics, which may have influenced metabolic responses and treatment-related toxicities. Similarly, although permutation testing supported the robustness of the OPLS–DA models, the relatively small sample size and lack of external validation increase the risk of model overfitting, and the multivariate findings should therefore be interpreted cautiously.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.